Aurinia Pharmaceuticals (AUPH) Receives a Buy from Cantor Fitzgerald


Cantor Fitzgerald analyst Elemer Piros maintained a Buy rating on Aurinia Pharmaceuticals (AUPH) today and set a price target of $18. The company’s shares closed on Friday at $7.55, close to its 52-week high of $7.85.

Piros commented:

“We rate Aurinia Pharmaceuticals Overweight. Aurinia is developing a cyclosporine drug analog, voclosporin, for the treatment of lupus nephritis. Voclosporin is the first development candidate to achieve a successful primary readout in a large global randomized trial for lupus nephritis. Aurinia is conducting a single pivotal Phase 3 AURORA study, which completed enrollment in September 2018. To-date, there remains no approved therapy for lupus nephritis in the U.S.”

According to TipRanks.com, Piros has 0 stars on 0-5 star ranking scale with an average return of -9.2% and a 38.7% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Proteostasis Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aurinia Pharmaceuticals with a $16.50 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $7.85 and a one-year low of $4.76. Currently, Aurinia Pharmaceuticals has an average volume of 797.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aurinia Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts